ClinicalTrials.gg
RecruitingNCT06475118MyomachiaUpdated Nov 16, 2026

Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma

An interventional study of Dynamometry measurement, myokine dosing, sarcopenia calculation in Sarcopenia and Hepatocellular Carcinoma, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by CHU de Reims · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Sarcopenia with a site in France — 23 open to participants now, 24 under way, none of them phase 3. Sarcopenia · France.

Planned enrollment
22nd of 53
139 · median 98
Started
2024
with 5 others
No phase
49 of 78
18 open now
Primary completion
2027-11
later than 15 of 23 live
Registered
64th of 78
by date
Lead sponsor
3 of 78
CHU de Reims

Among the 78 studies in Sarcopenia with a site in France, this one is the 22nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2024, is one of 49 with no phase, reaches primary completion later than 15 of the 23 other live ones, and was the 64th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

23 of the 78 studies in Sarcopenia with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Sarcopenia with a site in France, or all of them as a file.
02

Study summary

It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory substances in the blood can also contribute to muscle loss. Sarcopenia is assessed by an imaging technique called 'Skeletal Muscle Mass Index (SMI)' to measure muscle mass. This analysis can be done from radiological examinations. Sarcopenia has a serious impact on patients with hepatocellular carcinoma. It increases the risk of death, cancer recurrence, and decreases the response to treatments. Therefore, the investigators want to determine if blood tests for myokines obtained by simple blood draw can improve the assessment of sarcopenia in this specific setting.

Read the detailed description

Background:

Sarcopenia, which is a reduction of muscle mass and function, frequently occurs from the age of 40 and is exacerbated by diseases such as cirrhosis, chronic inflammation, and cancer. It is well established that sarcopenia impairs quality of life and promotes the occurrence of complications. Myostatin, a muscle hormone (myokine), contributes to sarcopenia by promoting muscle degradation. Conversely, follistatin, an antagonist of myostatin, may play a role in maintaining muscle mass and protein synthesis. Irisin, another myokine, can protect against muscle atrophy and improve metabolism. Inflammatory cytokines like TNF-α and IL-6 can also contribute to sarcopenia by promoting muscle degradation. To evaluate sarcopenia in patients with cirrhosis and cancer, the most commonly used method is the calculation of the Skeletal Muscle Index (SMI) at the third lumbar vertebra (L3 SMI: Total Muscle Surface at L3 in cm²/ Height in m²). Other methods can also be used, but are susceptible to being influenced by water retention, particularly in cirrhotic patients. In patients with cirrhosis, sarcopenia negatively impacts quality of life and is associated with an increased risk of serious complications. In patients with hepatocellular carcinoma (HCC), it increases mortality, tumor recurrence, and reduces the response to treatments. Thus, its assessment and management are essential to improve the quality of life and prognosis of these patients. The validation of biological diagnostic criteria for sarcopenia would facilitate diagnosis and ensure follow-up without resorting to repetitive imaging.

Materials and Methods:

Type of study: Prospective validation study of a diagnostic method

Judgment criteria:

  • Serum concentrations of myostatin, follistatin, and irisin
  • Muscle surface calculated at L3 and parameterized according to height (L3 SMI)
  • Muscle strength assessed by dynamometry

Investigation plan:

  1. Screening of Patient after discussion in Multidisciplinary Liver Cancer Board
  2. Proposal of the study during the announcement consultation after RCP.
  3. Blood sampling during standard pre-therapeutic care and dynamometry measurement
  4. Retrieval of scanographic imaging and calculation of the L3 SMI index
  5. Blood dosages of myokines
  6. Statistical analyses

Schedule:

  • April 2024-July 2024: CPP evaluation
  • August 2024-July 2025: Inclusion period.
  • August 2024-July 2025: Radiological analyses (in parallel with the inclusions). Selection of available imagery, extraction of key images. Analysis of muscle mass and calculation of the L3 SMI index.
  • August 2024-July 2025: Biological analyses (in parallel with the radiological analyses). Measurement of blood concentrations of myokines.
  • August 2025-April 2026: Statistical analyses and article writing.

Expected Results and Prospects:

The current priority og investigators is to validate rapid and effective serum markers to facilitate the early diagnosis and clinical follow-up of sarcopenia in patients with hepatocellular carcinoma. In the long term, the goal is to implement early interventions aimed at mitigating the effects of sarcopenia. These serum markers could improve the management of liver diseases and cancers as key prognostic factors. The results of this study will also contribute to a better pathophysiological understanding of sarcopenia in these patients.

03

Conditions studied

  • Sarcopenia
  • Hepatocellular Carcinoma

Keywords

  • Sarcopenia
  • Hepatocellular Carcinoma
  • myokines
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • New diagnosis of HCC,or diagnosis of recurrence of HCC in a previously treated patient, for more than 6 months, made by radiology and/or histopathology according to EASL criteria, regardless of the degree of hepatic fibrosis (METAVIR F0-F4)
  • Availability of a pre-therapeutic three-phase contrast-enhanced abdominal-pelvic CT scan.

Non-inclusion criteria:

  • Presence of an active cancer other than HCC
  • Uncontrolled infection
  • Recurrence of HCC after treatment 6 months or less ago
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (estimated)

Study arms

  • Experimental
    Patients with hepatocellular carcinoma

    Other: Dynamometry measurement, myokine dosing, sarcopenia calculation

Interventions

  • OtherDynamometry measurement, myokine dosing, sarcopenia calculation

    Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index

06

What researchers measure

Primary outcomes

  1. Determine if serum myokines measured in patients with HCC are correlated with muscle mass index assessed by standard scanographic technique.

    Analysis of correlation between serum myokines measured in patients with HCC and muscle mass index assessed by standard scanographic technique

    Time frame: Day 1

Secondary outcomes

  1. Determine the serum myokine concentration threshold for the diagnosis of sarcopenia defined by an L3 SMI < 50 cm2/m2 in men

    Analysis of correlation between serum myokines thresholds in patients with HCC and sarcopenia defined by an L3 SMI \< 50 cm\^2/m\^2 in men

    Time frame: Day 1

  2. Determine the serum myokine concentration threshold for the diagnosis of sarcopenia defined by an L3 SMI < 39 cm2/m2 in women

    Analysis of correlation between serum myokines thresholds in patients with HCC and sarcopenia defined by an L3 SMI \< 39 cm\^2/m\^2 in women

    Time frame: Day 1

  3. Determine if serum myokines measured in patients with HCC are correlated with muscle strength assessed by dynamometry

    Analysis of correlation between serum myokines measured in patients with HCC and Muscle strength assessed by dynamometry

    Time frame: Day 1

  4. Determine if inflammatory cytokines (IL6, TNFα) measured in patients with HCC are correlated with muscle mass index assessed by the standard scanographic technique

    Analysis of correlation between inflammatory cytokines (IL6, TNFα) measured in patients with HCC and muscle mass index assessed by the standard scanographic technique

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2027, 36 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 36 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2025 → Nov 2027 and completion May 2026 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jun 26, 2024
StartActual
Nov 22, 2024
Primary completionEst.
Nov 22, 2027was Nov 2025
CompletionEst.
May 22, 2028was May 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 22, 2025→Nov 22, 2027
Nov 16, 2026
Study completion
May 22, 2026→May 22, 2028
Nov 16, 2026
Eligibility
1 criterion edited, 1 added
What changed in the criteria
  • EditedNew diagnosis of HCC,or diagnosis of recurrence of HCC in a previously treated patient, for more than 6 months, made by radiology and/or histopathology according to EASL criteria, regardless of the degree of hepatic fibrosis (METAVIR F0-F4)
  • AddedRecurrence of HCC after treatment 6 months or less ago
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Nov 22, 2025→Nov 22, 2027
    Study completion May 22, 2026→May 22, 2028
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • EditedNew diagnosis of HCC,or diagnosis of recurrence of HCC in a previously treated patient, for more than 6 months, made by radiology and/or histopathology according to EASL criteria, regardless of the degree of hepatic fibrosis (METAVIR F0-F4)
    • AddedRecurrence of HCC after treatment 6 months or less ago
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06475118
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Nov 22, 2024
Primary completion
Nov 22, 2027 (estimated)
Completion
May 22, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Elia GIGANTE
Contact
egigante@chu-reims.fr
03 26 78 33 43 ext. 0033

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion